ReviewTranslational lung cancer research2019
Combining stereotactic body radiation therapy with immunotherapy: current data and future directions.
Review in Translational lung cancer research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- MR-Guided Adaptive Radiotherapy in Lung Cancer: Current Landscape and Future Directions.Cancers · 2026Review
- Reframing the paradigm: stereotactic body radiation therapy as an engineer of the tumor immune microenvironment.Frontiers in immunology · 2026Review
- The Treatment of Patients with Early-Stage Non-Small Cell Lung Cancer Who Are Not Candidates or Decline Surgical Resection: The Role of Radiation and Image-Guided Thermal Ablation.Journal of clinical medicine · 2024Review
- Immunotherapy in the Battle Against Bone Metastases: Mechanisms and Emerging Treatments.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Efficacy and prognostic factors of stereotactic body radiotherapy combined with immunotherapy for pulmonary oligometastases: a preliminary retrospective cohort study.Translational lung cancer research · 2024Article
- The analysis of the efficacy and safety of stereotactic body radiotherapy with sequential immune checkpoint inhibitors in the management of oligoprogressive advanced non-small cell lung cancer.Translational cancer research · 2024Article
- Immunoradiotherapy for NSCLC: mechanisms, clinical outcomes, and future directions.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Review
- Harnessing the Immunological Effects of Radiation to Improve Immunotherapies in Cancer.International journal of molecular sciences · 2023Review
- Systemic immune modulation by stereotactic radiotherapy in early-stage lung cancer.NPJ precision oncology · 2023Article
- Tumor microenvironment shows an immunological abscopal effect in patients with NSCLC treated with pembrolizumab-radiotherapy combination.Journal for immunotherapy of cancer · 2022Article
- Article
- Outcome of lung oligometastatic patients treated with stereotactic body irradiation.Frontiers in oncology · 2022Article
- The potential of biology-guided radiation therapy in thoracic cancer: A preliminary treatment planning study.Frontiers in oncology · 2022Article
- Combing stereotactic body radiotherapy with checkpoint inhibitors after oligoprogression in advanced non-small cell lung cancer.Translational lung cancer research · 2021Article
- New challenges in the combination of radiotherapy and immunotherapy in non-small cell lung cancer.World journal of clinical oncology · 2021Review
- Oligoprogression in Non-Small Cell Lung Cancer.Cancers · 2021Review
- Local administration of submicron particle paclitaxel to solid carcinomas induces direct cytotoxicity and immune-mediated tumoricidal effects without local or systemic toxicity: preclinical and clinical studies.Drug delivery and translational research · 2021Review
- Impact of pre-treatment C-reactive protein level and skeletal muscle mass on outcomes after stereotactic body radiotherapy for T1N0M0 non-small cell lung cancer: a supplementary analysis of the Japan Clinical Oncology Group study JCOG0403.Journal of radiation research · 2021Article
- Effect of prior thoracic radiotherapy on prognosis in relapsed small cell lung cancer patients treated with anlotinib: a subgroup analysis of the ALTER 1202 trial.Translational lung cancer research · 2021Article
- Lung cancer dynamics using fractional order impedance modeling on a mimicked lung tumor setup.Journal of advanced research · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stereotactic body radiation therapy (SBRT) offers excellent local control of early-stage non-small cell lung cancer (NSCLC), but there currently is a need for tolerable systemic therapy to address regional and distant disease progression. One potential option is immunotherapy, which in metastatic NSCLC has shown promise for sustained disease control in a subset of patients. There is also growing evidence for a clinical synergy between radiation and immunotherapy, with several ongoing trials studying the abscopal effect. This review summarizes the current data in the fast-changing field of immuno-radiation therapy, highlighting updates from recent clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.